These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 23929928)

  • 1. Randomized controlled trial of febuxostat versus allopurinol or placebo in individuals with higher urinary uric acid excretion and calcium stones.
    Goldfarb DS; MacDonald PA; Gunawardhana L; Chefo S; McLean L
    Clin J Am Soc Nephrol; 2013 Nov; 8(11):1960-7. PubMed ID: 23929928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia.
    Huang X; Du H; Gu J; Zhao D; Jiang L; Li X; Zuo X; Liu Y; Li Z; Li X; Zhu P; Li J; Zhang Z; Huang A; Zhang Y; Bao C
    Int J Rheum Dis; 2014 Jul; 17(6):679-86. PubMed ID: 24467549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. As compared to allopurinol, urate-lowering therapy with febuxostat has superior effects on oxidative stress and pulse wave velocity in patients with severe chronic tophaceous gout.
    Tausche AK; Christoph M; Forkmann M; Richter U; Kopprasch S; Bielitz C; Aringer M; Wunderlich C
    Rheumatol Int; 2014 Jan; 34(1):101-9. PubMed ID: 24026528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Febuxostat compared with allopurinol in patients with hyperuricemia and gout.
    Becker MA; Schumacher HR; Wortmann RL; MacDonald PA; Eustace D; Palo WA; Streit J; Joseph-Ridge N
    N Engl J Med; 2005 Dec; 353(23):2450-61. PubMed ID: 16339094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of calcium nephrolithiasis in the patient with hyperuricosuria.
    Arowojolu O; Goldfarb DS
    J Nephrol; 2014 Dec; 27(6):601-5. PubMed ID: 24687403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.
    Schumacher HR; Becker MA; Wortmann RL; Macdonald PA; Hunt B; Streit J; Lademacher C; Joseph-Ridge N
    Arthritis Rheum; 2008 Nov; 59(11):1540-8. PubMed ID: 18975369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diabetes and gout: efficacy and safety of febuxostat and allopurinol.
    Becker MA; MacDonald PA; Hunt BJ; Jackson RL
    Diabetes Obes Metab; 2013 Nov; 15(11):1049-55. PubMed ID: 23683134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Febuxostat on Ambulatory Blood Pressure in Subjects With Hyperuricemia and Hypertension: A Phase 2 Randomized Placebo-Controlled Study.
    Gunawardhana L; McLean L; Punzi HA; Hunt B; Palmer RN; Whelton A; Feig DI
    J Am Heart Assoc; 2017 Nov; 6(11):. PubMed ID: 29102979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout.
    Ernst ME; Fravel MA
    Clin Ther; 2009 Nov; 31(11):2503-18. PubMed ID: 20109996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age.
    Jackson RL; Hunt B; MacDonald PA
    BMC Geriatr; 2012 Mar; 12():11. PubMed ID: 22436129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of recurrent uric acid and calcium oxalate stones by administration of the xanthine oxidase inhibitors Milurit 100 and Milurit 300.
    Schneider HJ; Brundig P; Balogh A; Traeger A; Stein G; Fünfstück R
    Int Urol Nephrol; 1983; 15(2):121-9. PubMed ID: 6688800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Placebo-controlled, double-blind study of the non-purine-selective xanthine oxidase inhibitor Febuxostat (TMX-67) in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study.
    Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
    J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S19-26. PubMed ID: 21654266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Febuxostat for treating chronic gout.
    Tayar JH; Lopez-Olivo MA; Suarez-Almazor ME
    Cochrane Database Syst Rev; 2012 Nov; 11(11):CD008653. PubMed ID: 23152264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Febuxostat in gout: serum urate response in uric acid overproducers and underexcretors.
    Goldfarb DS; MacDonald PA; Hunt B; Gunawardhana L
    J Rheumatol; 2011 Jul; 38(7):1385-9. PubMed ID: 21572152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout.
    Becker MA; Schumacher HR; Wortmann RL; MacDonald PA; Palo WA; Eustace D; Vernillet L; Joseph-Ridge N
    Arthritis Rheum; 2005 Mar; 52(3):916-23. PubMed ID: 15751090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The hyperuricosuric calcium oxalate stone former.
    Sarig S
    Miner Electrolyte Metab; 1987; 13(4):251-6. PubMed ID: 3306317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lesinurad: A Review in Hyperuricaemia of Gout.
    Deeks ED
    Drugs Aging; 2017 May; 34(5):401-410. PubMed ID: 28425024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Twenty-Four Hour Urine Testing and Prescriptions for Urinary Stone Disease-Related Medications in Veterans.
    Song S; Thomas IC; Ganesan C; Sohlberg EM; Chertow GM; Liao JC; Conti S; Elliott CS; Pao AC; Leppert JT
    Clin J Am Soc Nephrol; 2019 Dec; 14(12):1773-1780. PubMed ID: 31712387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An allopurinol-controlled, multicenter, randomized, open-label, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 2 exploratory clinical study.
    Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
    J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S44-9. PubMed ID: 21654269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Change in inhibitory potential in urine of hyperuricosuric calcium oxalate stone formers effected by allopurinol and orthophosphates.
    Goldwasser B; Sarig S; Azoury R; Wax Y; Hirsch D; Perlberg S; Many M
    J Urol; 1984 Nov; 132(5):1008-11. PubMed ID: 6492268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.